Adverse events in the mother ‐ Bleeding · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes adverse events in the mother ‐ Bleeding compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · preventing acute otitis media in children up to 12 years of age
Xylitol showed no clear difference in gastrointestinal‐related adverse events compared with control (moderate certainty).
3 findings from 1 review
RR 1.04 [0.92, 1.16]
1 study · 326 participants
Moderate
RR 1.43 [0.74, 2.75]
3 studies · 1826 participants
Moderate
RR 2.82 [0.61, 13]
1 study · 1277 participants
Moderate
Adverse events: active lotion vs placebo · individuals at risk of pressure ulcer development
It is very uncertain whether active topical agent changes adverse events: active lotion vs placebo compared with placebo/control (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐Infected Pregnant Women With CD4<350
It is very uncertain whether jamisse (What to Start): AZT/3TC/NVP changes maternal Grade 3/4 Severe Adverse Events compared with d4T/3TC/NVP (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected pregnant women
It is very uncertain whether jamisse (When to Start): AZT/3TC/NVP for CD4 250‐350 changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3
It is very uncertain whether phanuphak: AZT/3TC/NVP (PMTCT) changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (ART) (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: death (secondary outcome) compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: death (secondary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events due to periodontal therapy · People with periodontitis and metabolic syndrome (no CVD; primary prevention)
It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes adverse events due to periodontal therapy compared with supragingival scaling (plus placebo) (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events for neonate/infant · pregnant women and their babies
The intervention may leads to lower serious adverse events for neonate/infant (low certainty).
1 finding from 1 review
Adverse events (pain on dressing removal) · people with pressure ulcers
Hydrogel dressings showed no clear difference in adverse events (pain on dressing removal) compared with hydrogel dressings (low certainty).
1 finding from 1 review
Urinary tract infection · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes adverse events ‐ Urinary tract infections compared with methylprednisolone (very low certainty).
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
It is very uncertain whether long‐term red cell transfusion changes adverse events associated with transfusion compared with no transfusion (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events, complications and morbidity associated with (adeno)tonsillectomy and comparators Expressed as the proportion of children experiencing adverse events [12 months] · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Intervention not reported
Adverse events, complications and morbidity associated with (adeno)tonsillectomy and comparators Expressed as the proportion of children experiencing a serious adverse event [7 months] · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Adverse events: arteriovenous complications · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: arteriovenous complications compared with with every two weeks (low certainty).
1 finding from 1 review